Clinical Trial News and Research

RSS

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

9 Mar 2023

Revolutionary drug blocks a gene associated with driving the spread of bone cancer

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer.

8 Mar 2023

Randomness governs the responsiveness of tumor cells to chemotherapy

According to a recent study done by the Garvan Institute of Medical Research, cancer cells have an inbuilt unpredictability in their capacity to respond to chemotherapy, which is another tool in their armory for fighting treatment.

6 Mar 2023

Cell therapy trial promises long-term improvement for patients with chronic heart failure

Physician-scientists at The Texas Heart Institute announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction.

28 Feb 2023

Study: Oral verapamil improves the pancreas' insulin secretion in children with newly-diagnosed TID

Published in JAMA, a University of Minnesota led study shows that verapamil, a drug commonly used to treat high blood pressure and heart conditions, can have a beneficial effect on the pancreas in children with newly-diagnosed type 1 diabetes (T1D).

27 Feb 2023

Insilico Medicine: IND application for first generative AI-designed drug for COVID-19 approved

Insilico Medicine, a clinical-stage biotech company powered by generative AI, today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ISM3312, an orally available 3CLpro inhibitor generated and designed with the support of Insilico's proprietary generative chemistry platform Chemistry42 for the treatment of COVID-19.

24 Feb 2023

Mount Sinai researchers reveal mechanisms underlying autoimmunity in Down syndrome

Scientists at the Icahn School of Medicine at Mount Sinai in New York have identified which parts of the immune system go awry and contribute to autoimmune diseases in individuals with Down syndrome.

23 Feb 2023

Study shows how convalescent plasma can be used as effective treatment during future pandemics

Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe.

22 Feb 2023

Substituting meat for mycoprotein reduces intestinal genotoxins, increases healthy gut bacteria

Researchers from Northumbria University have found that swapping red and processed meat for Quorn's mycoprotein, a fungi-based meat alternative, leads to a significant reduction in intestinal genotoxins - which can cause bowel cancer - and increases healthy gut bacteria.

17 Feb 2023

Effect of prune supplementation on the gut microbiome of postmenopausal women

New research published in the journal Food & Function indicates that daily prune consumption may improve the gut fecal microbiome of postmenopausal women. The fecal microbiome – the ecosystem of microorganisms found in one's fecal matter – reflects an individual's overall gut health. Results from the study showed notable enrichment in bacteria from the family Lachnospiraceae. This group of bacteria has been associated with an ability to decrease inflammatory markers in the body and help maintain the integrity of the gut barrier.

16 Feb 2023

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.

15 Feb 2023

Study charts seasonal and circadian genetic variation across the human body

The daily rotation of Earth and its yearly voyage around the Sun marks the natural rhythm of life on the planet.

14 Feb 2023

Blastocystis can promote or disrupt gut health, study finds

The gut microbiota contains trillions of bacteria that can promote health or cause disease under different conditions.

14 Feb 2023

Oral difelikefalin could reduce the intensity of itch in patients with notalgia paresthetica

Notalgia paresthetica-;a nerve disorder characterized by a persistent itch in the upper back-;is a common and underdiagnosed condition worldwide.

9 Feb 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023

Treating ovarian cancer with immunotherapy involving CAR T cells

Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.

7 Feb 2023

CAR T-cell therapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Cerba Research announced today a Memorandum of Understanding with Teddy Clinical Research Laboratory (Wuxi, China), a preeminent central lab provider covering mainland China, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture.

From Cerba Research 3 Feb 2023

AI-based strategy helps discover high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

31 Jan 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023